Pay in 4 interest-free payments of $5.45 Learn more
Ships within 48 hours · Estimated delivery Sep 22 - Sep 27
Compounding market transition (Feb 6, 2026): The FDA announced a major enforcement action specifically targeting "mass-marketed" compounded GLP-1 alternatives
Insurance covers it but excludes Wegovy
Two studies were assessed as having high other bias because of their small sample sizes
GLP-1s account for 8% of all US prescriptions GLP-1 RA prescribing has reached a new milestone, with nearly 8% of all prescriptions in March 2026 attributed to these therapies following the largest quarter-over-quarter percentage point increase in overall GLP-1 RA prescribing observed since the study began in 2019
US$ 26.16
US$ 23.71
:format(webp))
US$ 22.53
